Piletz J E, Schubert D S, Halaris A
Life Sci. 1986 Nov 3;39(18):1589-616. doi: 10.1016/0024-3205(86)90156-6.
Discrepant results have been reported from at least ten laboratories regarding the status of platelet alpha 2 adrenoreceptors in depressed patients. Using a statistical test to combine those studies which utilized radioligand binding techniques, we find the overall data support an elevation in density of platelet alpha 2 adrenoreceptors from drug-free depressed patients (p less than 0.05) and suggest a normalization to lower binding values following antidepressant drug treatment (0.05 less than p less than 0.10). However, these positive results are attributable to highly significant findings by only three laboratories. Much of the discrepancy may be attributable to numerous methodological variables which distinguish the studies. Foremost amongst these variables are the use of different platelet size populations, the use of different medium, and the choice of radioactive ligand and competitor (non-radioactive ligand) in the assay. We present a rationale for the proper choice of each methodological condition used in the clinical assessment of platelet alpha 2 adrenoreceptor status, hoping that improved experimental designs will resolve the current controversy.
至少有十个实验室报告了关于抑郁症患者血小板α2肾上腺素能受体状态的不一致结果。通过统计检验来合并那些使用放射性配体结合技术的研究,我们发现总体数据支持未服用药物的抑郁症患者血小板α2肾上腺素能受体密度升高(p<0.05),并表明抗抑郁药物治疗后结合值降低至正常水平(0.05<p<0.10)。然而,这些阳性结果仅归因于三个实验室的高度显著发现。大部分差异可能归因于区分这些研究的众多方法学变量。这些变量中最主要的是使用不同大小的血小板群体、使用不同的培养基以及在测定中选择放射性配体和竞争者(非放射性配体)。我们提出了在临床评估血小板α2肾上腺素能受体状态时正确选择每种方法学条件的基本原理,希望改进的实验设计能够解决当前的争议。